A Phase 2, Multi-Center, Open-Label, Randomized Trial of Gemcitabine/ Carboplatin, With or Without BSI-201, in Patients With ER, PR and HER2-Negative Metastatic Breast Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

26 May 2011 Actual end date changed from 11 Dec 2009 to Jun 2010 as reported by ClinicalTrials.gov.
12 Oct 2010 Final efficacy results were presented at the 35th Congress of the European Society for Medical Oncology.
10 Oct 2010 Regulatory submissions are planned for Q1 2011 in the US and Q2 2011 in the EU, according to a sanofi aventis and BiPar Sciences media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com